https://crstodayeurope.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/daily0.7https://crstodayeurope.com/news/zenni-releases-new-anti-fog-glasses-lenses-to-address-mask-related-fogging/2478797/daily0.7https://crstodayeurope.com/news/leo-lens-pharma-announces-corporate-name-change-to-mediprint-ophthalmics/2478794/daily0.7https://crstodayeurope.com/news/center-for-sight-is-the-first-practice-worldwide-to-offer-the-optiblue-iol/2478793/daily0.7https://crstodayeurope.com/news/merck-shuts-down-covid-vaccine-program-after-lackluster-data/2478791/daily0.7https://crstodayeurope.com/news/ace-vision-group-closes-series-a-stock-round-to-advance-ophthalmic-technologies/2478790/daily0.7https://crstodayeurope.com/news/ftc-to-probe-physician-practice-consolidation-and-impact-on-market-competition/2478787/daily0.7https://crstodayeurope.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/daily0.7https://crstodayeurope.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/daily0.7https://crstodayeurope.com/news/preliminary-results-from-aldeyras-phase-3-tranquility-trial-offer-promise-for-patients-with-dry-eye-syndrome-says-globaldata/2478786/daily0.7https://crstodayeurope.com/news/new-global-survey-underscores-need-for-myopia-education-and-evidence-based-approaches/2478783/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/daily0.7https://crstodayeurope.com/news/surface-ophthalmics-announces-positive-topline-results-from-phase-2-trial-for-surf-201-for-the-treatment-of-post-cataract-surgery-pain-and-inflammation/2478781/daily0.7https://crstodayeurope.com/news/new-data-back-ability-of-pfizer-biontechs-covid-19-vaccine-to-foil-uk-strain/2478782/daily0.7https://crstodayeurope.com/news/alcon-launches-precision1-for-astigmatism-contact-lenses-in-the-us/2478780/daily0.7https://crstodayeurope.com/news/vsy-biotechnology-introduces-protectalon-duo-kit/2478778/daily0.7https://crstodayeurope.com/news/ocuphire-announces-publication-of-orion-1-phase-2-results-for-nyxol-in-clinical-ophthalmology/2478779/daily0.7https://crstodayeurope.com/news/eyecare-partners-acquires-of-several-oklahoma-based-independent-ophthalmology-practices/2478776/daily0.7https://crstodayeurope.com/news/righteye-launches-new-version-4-0-to-its-eye-tracking-technology/2478777/daily0.7https://crstodayeurope.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/daily0.7https://crstodayeurope.com/news/rayner-enters-canadian-ophthalmology-market/2478773/daily0.7https://crstodayeurope.com/news/more-adults-with-vision-loss-seeking-help-staying-connected-during-pandemic/2478772/daily0.7https://crstodayeurope.com/news/coopervision-announces-5-mm-bozd-customization-for-paragon-crt-and-crt-dual-axis-lenses/2478769/daily0.7https://crstodayeurope.com/news/bausch-lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane/2478770/daily0.7https://crstodayeurope.com/news/topcon-announces-eyerise-2021-virtual-symposia-expo/2478765/daily0.7https://crstodayeurope.com/news/smart-contact-lens-targets-vision-improvement-for-those-with-impairments/2478766/daily0.7https://crstodayeurope.com/news/study-implandatas-eyemate-system-protects-glaucoma-patients-even-during-lockdown/2478767/daily0.7https://crstodayeurope.com/news/biden-picks-former-fda-commissioner-david-kessler-to-lead-operation-warp-speed/2478768/daily0.7https://crstodayeurope.com/news/james-reid-named-ceo-of-versant-health/2478762/daily0.7https://crstodayeurope.com/news/printable-chart-suitable-for-stay-at-home-visual-evaluation/2478763/daily0.7https://crstodayeurope.com/news/sources-fda-veteran-woodcock-being-considered-to-lead-agency-under-biden/2478764/daily0.7https://crstodayeurope.com/news/cdc-expands-negative-covid-19-test-requirement-to-all-air-passengers-entering-the-united-states/2478761/daily0.7https://crstodayeurope.com/news/avellino-exceeds-1-million-covid-19-tests-in-2020-and-welcomes-new-executive-team-hires-in-2021/2478756/daily0.7https://crstodayeurope.com/news/jpm-how-did-pfizer-up-its-covid-19-vaccine-capacity-out-of-the-box-manufacturing-ceo-says/2478757/daily0.7https://crstodayeurope.com/news/ntc-grants-to-zhaoke-exclusive-license-and-distribution-rights-in-asia-for-ntc014-for-bacterial-conjunctivitis/2478758/daily0.7https://crstodayeurope.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/daily0.7https://crstodayeurope.com/news/cvp-welcomes-three-new-ophthalmology-partner-practices/2478760/daily0.7https://crstodayeurope.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/daily0.7https://crstodayeurope.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/daily0.7https://crstodayeurope.com/news/pacific-vision-surgery-center-opens-doors-to-bay-area-community/2478751/daily0.7https://crstodayeurope.com/news/ema-receives-conditional-marketing-request-for-astrazenecas-covid-19-vaccine/2478752/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-names-new-clinical-director/2478749/daily0.7https://crstodayeurope.com/news/notal-vision-launches-first-us-home-oct-longitudinal-study-with-patient-self-operated-device/2478748/daily0.7https://crstodayeurope.com/news/jpm-biontech-hikes-covid-19-vaccine-output-to-2b-doses-in-2021-and-plans-a-bigger-label-too/2478746/daily0.7https://crstodayeurope.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/daily0.7https://crstodayeurope.com/news/enchroma-names-vision-industry-veteran-erik-ritchie-as-ceo/2478743/daily0.7https://crstodayeurope.com/news/corneat-visions-first-patient-regains-sight-following-artificial-cornea-implantation-at-rabin-medical-center/2478741/daily0.7https://crstodayeurope.com/news/eyesouth-partners-expands-network-to-include-28-doctors-in-ohio-and-kentucky-through-affiliation-with-midwest-eye-center/2478742/daily0.7https://crstodayeurope.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-treatment-roclanda/2478740/daily0.7https://crstodayeurope.com/news/bayer-strikes-alliance-to-advance-curevacs-covid-19-vaccine-cvncov/2478735/daily0.7https://crstodayeurope.com/news/aha-presses-for-changes-to-covid-19-vaccine-rollout-and-for-hhs-to-take-larger-role/2478736/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-promotes-michael-goldstein-md-mba-to-president-ophthalmology/2478733/daily0.7https://crstodayeurope.com/news/haag-streit-introduces-lenstar-myopia-for-myopia-management/2478732/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-commercial-availability-of-eysuvis-for-the-treatment-of-dry-eye-disease/2478729/daily0.7https://crstodayeurope.com/news/iacta-pharmaceuticals-and-pharmaleads-to-develop-the-worlds-first-epithelial-protective-drug-harnessing-endogenous-analgesia-for-the-topical-treatment-of-acute-and-chronic-ocular-pain/2478730/daily0.7https://crstodayeurope.com/news/alcon-launches-acrysof-iq-vivity-extended-depth-of-focus-iol-in-us/2478731/daily0.7https://crstodayeurope.com/news/modernas-covid-19-vaccine-becomes-second-to-nab-eu-authorization/2478725/daily0.7https://crstodayeurope.com/news/sifi-launches-dry-eye-disease-synfo/2478726/daily0.7https://crstodayeurope.com/news/birmingham-research-paves-the-way-for-new-anti-fibrotic-therapy-for-glaucoma/2478727/daily0.7https://crstodayeurope.com/news/volk-optical-releases-clearpod-to-address-mask-related-fogging-during-fundus-examinations/2478724/daily0.7https://crstodayeurope.com/news/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis/2478719/daily0.7https://crstodayeurope.com/news/nicoxs-licensee-bausch-lomb-launches-vyzulta-in-mexico/2478720/daily0.7https://crstodayeurope.com/news/eyecare-associates-of-east-texas-announces-partnership-with-private-equity-firm-eyecare-partners/2478721/daily0.7https://crstodayeurope.com/news/study-hospitals-at-or-near-full-covid-19-icu-capacity-increase-by-90-over-past-few-months/2478722/daily0.7https://crstodayeurope.com/news/prevent-blindness-issues-call-for-nominations-for-two-awards/2478723/daily0.7https://crstodayeurope.com/news/norlase-receives-ce-mark-approval-for-lion-green-laser-system/2478718/daily0.7https://crstodayeurope.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/daily0.7https://crstodayeurope.com/news/fda-knocks-proposals-to-tinker-with-covid-19-vaccine-regimens/2478714/daily0.7https://crstodayeurope.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/daily0.7https://crstodayeurope.com/news/hi-health-launches-new-eye-care-division/2478716/daily0.7https://crstodayeurope.com/news/midwest-vision-partners-announces-partnership-with-parschauer-eye-center/2478711/daily0.7https://crstodayeurope.com/news/vision-innovation-partners-completes-17th-acquisition-eyes-of-york/2478708/daily0.7https://crstodayeurope.com/news/who-validates-pfizer-biontechs-covid-19-vaccine-for-emergency-use/2478709/daily0.7https://crstodayeurope.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/daily0.7https://crstodayeurope.com/news/physicians-react-doctors-worry-about-patients-reading-their-clinical-notes/2478707/daily0.7https://crstodayeurope.com/news/nicoxs-partner-ocumension-therapeutics-initiates-zerviate-phase-3-clinical-trial-in-china/2478704/daily0.7https://crstodayeurope.com/news/prevent-blindness-provides-variety-of-free-resources-educational-tools-in-support-of-januarys-national-glaucoma-awareness-month/2478702/daily0.7https://crstodayeurope.com/news/eyenovia-submits-nda-to-fda-for-pharmacologic-mydriasis-with-mydcombi/2478701/daily0.7https://crstodayeurope.com/news/three-optometry-practices-in-southwest-florida-partner-with-private-equity-firm-us-eye/2478699/daily0.7https://crstodayeurope.com/news/timing-of-cataract-removal-in-infancy-may-affect-glaucoma-risk/2478700/daily0.7https://crstodayeurope.com/news/haag-streit-uk-announce-the-launch-of-the-ivue80-in-the-uk/2478697/daily0.7https://crstodayeurope.com/news/innovent-announces-nmpa-granted-new-indication-approvals-for-sulinno-for-the-treatment-of-pediatric-plaque-psoriasis-and-noninfectious-uveitis/2478695/daily0.7https://crstodayeurope.com/news/iridex-announces-micropulse-transscleral-laser-therapy-now-accepted-in-the-european-glaucoma-society-guidelines/2478696/daily0.7https://crstodayeurope.com/news/nicoxs-licensee-bausch-lomb-secures-approval-of-vyzulta-in-colombia/2478694/daily0.7https://crstodayeurope.com/news/ocugen-and-bharat-biotech-to-co-develop-covaxin-covid-19-vaccine-for-the-us-market/2478692/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2478693/daily0.7https://crstodayeurope.com/news/from-covid-19-to-retail-health-fierce-healthcares-biggest-stories-of-2020/2478689/daily0.7https://crstodayeurope.com/news/norlase-announce-the-addition-of-distributor-partnerships/2478690/daily0.7https://crstodayeurope.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/daily0.7https://crstodayeurope.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/daily0.7https://crstodayeurope.com/news/eyegate-pharma-announces-acquisition-of-panoptes-pharma/2478685/daily0.7https://crstodayeurope.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/daily0.7https://crstodayeurope.com/news/federal-guidance-enables-employers-to-mandate-workers-get-covid-19-vaccine/2478682/daily0.7https://crstodayeurope.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/daily0.7https://crstodayeurope.com/news/nidek-launches-b-scan-denoising-software-with-deep-learning-to-enhance-oct-retinal-image-quality/2478684/daily0.7https://crstodayeurope.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/daily0.7https://crstodayeurope.com/news/demand-pay-for-travel-icu-nurses-soar-as-hospitals-face-staff-crunch-due-to-covid-19/2478681/daily0.7https://crstodayeurope.com/news/oyster-point-pharma-submits-nda-to-fda-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478677/daily0.7https://crstodayeurope.com/news/fda-panel-endorses-modernas-covid-19-vaccine-for-emergency-use/2478678/daily0.7https://crstodayeurope.com/news/aao-leading-advocates-for-seniors-timely-access-to-care-legislation-applaud-senate-bill-introduction/2478675/daily0.7https://crstodayeurope.com/news/2020-on-site-mobile-clinic-achieves-excellent-air-quality-and-professional-standards-with-steris-and-emmes-optym-certification/2478674/daily0.7https://crstodayeurope.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/daily0.7https://crstodayeurope.com/news/vsy-biotechnology-introduces-protectalon-duo-ovd-kit/2478673/daily0.7https://crstodayeurope.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/daily0.7https://crstodayeurope.com/news/verana-health-announces-the-start-of-a-new-patient-reported-outcomes-validation-study/2478669/daily0.7https://crstodayeurope.com/news/most-doses-of-lilly-regenerons-covid-19-antibody-treatments-are-going-unused/2478665/daily0.7https://crstodayeurope.com/news/fda-review-confirms-efficacy-of-modernas-mrna-1273-vaccine-against-covid-19/2478666/daily0.7https://crstodayeurope.com/news/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia/2478667/daily0.7https://crstodayeurope.com/news/envision-announces-dates-calls-for-submissions-for-2021-conferences/2478668/daily0.7https://crstodayeurope.com/news/medmont-launches-meridia-advanced-topographer/2478664/daily0.7https://crstodayeurope.com/news/optos-introduces-ultra-widefield-imaging-advancements/2478659/daily0.7https://crstodayeurope.com/news/new-data-reveal-how-treatment-tolerability-negative-patient-experiences-and-misinterpretation-of-iop-results-can-impact-glaucoma-management/2478660/daily0.7https://crstodayeurope.com/news/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease/2478661/daily0.7https://crstodayeurope.com/news/nicox-initiates-phase-2b-trial-of-ncx-4251-a-potential-first-in-class-treatment-for-blepharitis/2478662/daily0.7https://crstodayeurope.com/news/microsoft-rolls-out-covid-19-vaccine-management-platform-as-nationwide-distribution-gets-underway/2478663/daily0.7https://crstodayeurope.com/news/bruder-introduces-pre-surgical-patient-prep-kit/2478655/daily0.7https://crstodayeurope.com/news/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/2478656/daily0.7https://crstodayeurope.com/news/us-government-to-buy-100-million-more-doses-of-modernas-covid-19-vaccine/2478657/daily0.7https://crstodayeurope.com/news/hhs-proposes-changes-to-hipaa-privacy-rule-to-improve-care-coordination/2478653/daily0.7https://crstodayeurope.com/news/nicoxs-partner-fera-pharmaceuticals-to-investigate-naproxcinod-as-potential-covid-19-adjuvant-treatment/2478649/daily0.7https://crstodayeurope.com/news/fda-panel-endorses-pfizer-biontechs-covid-19-vaccine/2478650/daily0.7https://crstodayeurope.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/daily0.7https://crstodayeurope.com/news/foundation-fighting-blindness-appoints-peter-ginsberg-as-executive-vice-president-corporate-development-chief-business-officer/2478647/daily0.7https://crstodayeurope.com/news/canada-authorises-pfizer-biontechs-covid-19-vaccine/2478645/daily0.7https://crstodayeurope.com/news/mhra-advises-against-use-of-pfizer-biontechs-covid-19-vaccine-in-those-with-significant-history-of-allergic-reactions/2478646/daily0.7https://crstodayeurope.com/news/no-red-flags-in-fda-review-of-pfizer-biontechs-covid-19-vaccine-candidate/2478641/daily0.7https://crstodayeurope.com/news/the-cassini-ambient-now-compatible-with-the-catalys-precision-laser-system/2478642/daily0.7https://crstodayeurope.com/news/a-lifestyle-epidemic-ocular-surface-disease-workshop-to-address-vision-compromising-challenges/2478639/daily0.7https://crstodayeurope.com/news/norlase-announces-newly-appointed-distributors-into-major-european-markets/2478640/daily0.7https://crstodayeurope.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/daily0.7https://crstodayeurope.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/daily0.7https://crstodayeurope.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/daily0.7https://crstodayeurope.com/news/biden-builds-out-health-team-with-xavier-becerra-named-to-lead-hhs/2478635/daily0.7https://crstodayeurope.com/news/sifi-appoints-jelle-kleijn-to-lead-effort-to-deliver-first-registered-treatment-of-acanthamoeba-keratitis/2478631/daily0.7https://crstodayeurope.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/daily0.7https://crstodayeurope.com/news/katena-products-announces-steve-blazejewski-as-new-ceo/2478633/daily0.7https://crstodayeurope.com/news/zeiss-acquires-majority-stake-in-arivis-expands-imaging-technology-capabilities/2478629/daily0.7https://crstodayeurope.com/news/president-elect-biden-picks-california-attorney-general-to-lead-hhs/2478630/daily0.7https://crstodayeurope.com/news/registration-open-for-international-sports-vision-association-2021-virtual-annual-conference/2478628/daily0.7https://crstodayeurope.com/news/your-patient-plans-to-travel-despite-covid-19-risk-heres-the-latest-cdc-guidance-to-share/2478627/daily0.7https://crstodayeurope.com/news/cms-confirms-continued-separate-payment-for-omeros-fda-approved-omidria-in-ambulatory-surgery-centers/2478625/daily0.7https://crstodayeurope.com/news/supply-chain-snags-blamed-for-cut-to-pfizer-covid-19-vaccine-rollout-this-year-report/2478626/daily0.7https://crstodayeurope.com/news/cms-issues-final-2021-asc-payment-rule-2-4-increase-for-facilities/2478624/daily0.7https://crstodayeurope.com/news/effort-to-end-blindness-marks-milestone-with-leading-scientists-recognized-for-pioneering-work/2478623/daily0.7https://crstodayeurope.com/news/inmed-licenses-midrops-delivery-technology-from-eyecro-for-the-delivery-of-therapeutic-cannabinoids/2478621/daily0.7https://crstodayeurope.com/news/focus-vision-supplements-now-offer-eyelid-products-to-soothe-dry-eye-and-aid-in-postoperative-healing/2478622/daily0.7https://crstodayeurope.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/daily0.7https://crstodayeurope.com/news/fda-approves-eyenovias-ind-application-for-microline-for-presbyopia-allowing-for-phase-3-trials/2478620/daily0.7https://crstodayeurope.com/news/market-scope-cornea-products-market-to-grow-an-estimated-6-1-percent-through-2025/2478618/daily0.7https://crstodayeurope.com/news/topcon-announces-the-us-launch-of-rdx-telehealth-software-platform/2478617/daily0.7https://crstodayeurope.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/daily0.7https://crstodayeurope.com/news/medicare-cuts-jeopardize-patient-care-and-ignore-impacts-of-pandemic/2478611/daily0.7https://crstodayeurope.com/news/research-finds-little-progress-on-worldwide-blindness-in-a-decade/2478612/daily0.7https://crstodayeurope.com/news/cdc-panel-recommends-healthcare-workers-long-term-care-residents-and-staff-be-first-to-get-covid-19-vaccine/2478613/daily0.7https://crstodayeurope.com/news/uk-authorizes-use-of-pfizer-biontechs-covid-19-vaccine/2478614/daily0.7https://crstodayeurope.com/news/roche-receives-fda-emergency-use-authorization-for-new-covid-10-antibodies-test/2478610/daily0.7https://crstodayeurope.com/news/orbis-international-announces-mary-jane-jamar-as-first-chief-human-resources-officer/2478605/daily0.7https://crstodayeurope.com/news/alcon-canada-to-launch-a-professional-line-of-systane-ultra-hydration-lubricant-eye-drops-preservative-free/2478607/daily0.7https://crstodayeurope.com/news/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma/2478608/daily0.7https://crstodayeurope.com/news/hospital-operating-margins-down-nearly-20-since-start-of-year-due-to-covid-19-report-says/2478609/daily0.7https://crstodayeurope.com/news/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options/2478601/daily0.7https://crstodayeurope.com/news/alcon-joins-health-care-alliance-for-patient-safety/2478602/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-names-new-scientific-director/2478603/daily0.7https://crstodayeurope.com/news/vitamin-sciences-lauches-visivite-blue-light-basher-ocular-supplement/2478604/daily0.7https://crstodayeurope.com/news/john-weiss-secures-exclusive-uk-distributorship-for-vrmagics-eyesi-surgical-medical-simulator/2478600/daily0.7https://crstodayeurope.com/news/when-coronavirus-vaccines-are-ready-dentists-optometrists-may-give-shots/2478599/daily0.7https://crstodayeurope.com/news/dompe-and-the-farmamondo-group-enter-agreement-to-distribute-oxervate-in-russia-and-other-cis-countries/2478598/daily0.7https://crstodayeurope.com/news/eluminex-biosciences-announces-closing-of-50-million-series-a-financing/2478597/daily0.7https://crstodayeurope.com/news/modernas-mrna-covid-19-vaccine-94-1-effective-at-final-analysis/2478596/daily0.7https://crstodayeurope.com/news/jetblue-virgin-atlantic-set-to-roll-out-covid-19-health-pass-app-in-december/2478593/daily0.7https://crstodayeurope.com/news/uk-government-asks-regulator-to-clear-temporary-supply-of-astrazenecas-covid-19-vaccine/2478594/daily0.7https://crstodayeurope.com/news/core-and-myopia-profile-form-alliance-to-expand-clinical-research-and-professional-education-capabilities/2478595/daily0.7https://crstodayeurope.com/news/prediabetes-linked-to-macular-thinning/2478592/daily0.7https://crstodayeurope.com/news/report-dry-eye-treatment-devices-market-size-worth-400-8-million-by-2027/2478591/daily0.7https://crstodayeurope.com/news/bausch-health-initiates-second-phase-3-study-for-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2478590/daily0.7https://crstodayeurope.com/news/oculus-names-new-medical-director/2478589/daily0.7https://crstodayeurope.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/daily0.7https://crstodayeurope.com/news/fda-authorizes-regenerons-dual-covid-19-antibody-treatment-for-emergency-use/2478587/daily0.7https://crstodayeurope.com/news/astrazeneca-says-covid-19-vaccine-candidate-shows-70-efficacy/2478588/daily0.7https://crstodayeurope.com/news/white-house-finalizes-overhauls-of-stark-anti-kickback-statutes/2478585/daily0.7https://crstodayeurope.com/news/tarsus-pharmaceuticals-appoints-wendy-yarno-to-board-of-directors/2478584/daily0.7https://crstodayeurope.com/news/humanoptics-launches-triva-trifocal-iol/2478583/daily0.7https://crstodayeurope.com/news/topcon-announces-the-european-launch-of-chronos/2478579/daily0.7https://crstodayeurope.com/news/wayne-state-researchers-identify-cornea-as-a-potential-carrier-of-covid-19/2478580/daily0.7https://crstodayeurope.com/news/doctors-report-patients-health-declining-due-to-delayed-or-inaccessible-care-during-covid-19-pandemic/2478581/daily0.7https://crstodayeurope.com/news/data-confirm-immune-response-from-astrazenecas-covid-19-vaccine-in-elderly/2478582/daily0.7https://crstodayeurope.com/news/eversight-led-research-confirms-presence-of-sars-cov-2-in-postmortem-ocular-tissue/2478578/daily0.7https://crstodayeurope.com/news/sifi-completes-enrollment-of-the-phase-3-study-of-polihexanide-0-08-for-the-treatment-of-acanthamoeba-keratitis/2478575/daily0.7https://crstodayeurope.com/news/azar-expects-40m-covid-19-vaccine-doses-ready-to-distribute-by-end-of-december/2478576/daily0.7https://crstodayeurope.com/news/post-treatment-application-of-cryopreserved-amniotic-membrane-prokera-slim-may-be-useful-in-treating-infectious-corneal-ulcers/2478577/daily0.7https://crstodayeurope.com/news/despite-impressive-data-fdas-coronavirus-vaccine-reviews-will-take-weeks-not-days-official-says/2478574/daily0.7https://crstodayeurope.com/news/ceo-says-pfizer-very-close-to-filing-covid-19-vaccine-for-us-emergency-use/2478573/daily0.7https://crstodayeurope.com/news/pfizer-biontechs-covid-19-vaccine-shows-95-efficacy-rate-at-final-analysis/2478571/daily0.7https://crstodayeurope.com/news/hydrus-microstent-receives-highest-designation-of-any-migs-device-as-part-of-aao-treatment-guidelines/2478570/daily0.7https://crstodayeurope.com/news/amazon-unveils-pharmacy-offering-hitting-shares-of-drug-retailers/2478569/daily0.7https://crstodayeurope.com/news/alcon-canada-introduces-acrysof-iq-vivity-presbyopia-correcting-iol/2478568/daily0.7https://crstodayeurope.com/news/worlds-largest-specialty-clinical-data-registry-reveals-insights-into-eye-disease-prevention-and-treatment/2478566/daily0.7https://crstodayeurope.com/news/slit-lamp-breath-shields-proven-to-minimize-spread-of-droplets-that-can-carry-coronavirus-during-eye-exams/2478567/daily0.7https://crstodayeurope.com/news/one-year-after-fda-approval-misight-1-day-contact-lense280a8-mainstreams-myopia-management-in-the-u-s-e280a8e280a8/2478564/daily0.7https://crstodayeurope.com/news/topcon-announces-the-us-launch-of-chronos/2478562/daily0.7https://crstodayeurope.com/news/bausch-health-announces-investigational-in-vitro-data-indicating-complete-inactivation-of-sars-cov-2-with-lumify-and-besivance-eye-drops/2478558/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/daily0.7https://crstodayeurope.com/news/new-research-reveals-critical-role-of-ophthalmologists-in-maintaining-ongoing-dry-eye-disease-care-during-covid-19/2478554/daily0.7https://crstodayeurope.com/news/moderna-says-mrna-covid-19-vaccine-94-5-effective/2478555/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-provides-update-on-launch-plans-for-eysuvis-for-the-treatment-of-dry-eye-disease/2478550/daily0.7https://crstodayeurope.com/news/rural-hospitals-struggle-to-find-places-to-transfer-patients-amid-covid-19-surges/2478551/daily0.7https://crstodayeurope.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/daily0.7https://crstodayeurope.com/news/oyster-point-pharma-announces-clinical-data-presentations-on-oc-01-nasal-spray-for-dry-eye-disease-at-aao-virtual/2478548/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-roclanda-in-the-european-union/2478543/daily0.7https://crstodayeurope.com/news/astrazenecas-calquence-fails-to-help-patients-hospitalized-with-covid-19-respiratory-symptoms/2478544/daily0.7https://crstodayeurope.com/news/eyemd-emr-healthcare-systems-to-unveil-the-eyemd-emr-2-0-all-in-one-platform-at-aao-virtual/2478542/daily0.7https://crstodayeurope.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/daily0.7https://crstodayeurope.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/daily0.7https://crstodayeurope.com/news/adaptilens-announces-1-6-million-in-seed-funding-for-development-of-accommodating-iol/2478536/daily0.7https://crstodayeurope.com/news/sciencebased-health-announces-expansion-of-its-optometry-clinical-advisory-panel/2478537/daily0.7https://crstodayeurope.com/news/cdc-now-says-wearing-a-mask-protects-the-wearer-too/2478538/daily0.7https://crstodayeurope.com/news/zeiss-presents-integrated-workflow-advancements-at-aao/2478534/daily0.7https://crstodayeurope.com/news/american-academy-of-ophthalmology-leads-global-initiative-to-address-worldwide-myopia-epidemic/2478535/daily0.7https://crstodayeurope.com/news/zhaoke-ophthalmology-announced-first-patient-completes-3-year-enrollment-in-phase-3-myopia-trial/2478533/daily0.7https://crstodayeurope.com/news/wize-pharma-announces-positive-topline-results-in-phase-4-study-of-lo2a-for-dry-eye-in-patients-with-sjogrens-syndrome/2478529/daily0.7https://crstodayeurope.com/news/leo-lens-pharma-achieves-fda-ind-submission-and-seed-round-fundraising/2478530/daily0.7https://crstodayeurope.com/news/zeiss-introduces-video-laryngoscope/2478531/daily0.7https://crstodayeurope.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/daily0.7https://crstodayeurope.com/news/new-data-for-thyroid-eye-disease-treatment-tepezza-to-be-presented-at-aao-virtual/2478527/daily0.7https://crstodayeurope.com/news/russia-says-covid-19-vaccine-sputnik-v-92-effective-in-late-stage-study/2478524/daily0.7https://crstodayeurope.com/news/santen-to-present-glaucoma-ocularhypertension-data-at-aao-2020-virtual/2478519/daily0.7https://crstodayeurope.com/news/leiters-and-eyeconnect-international-announce-corporate-partnership/2478520/daily0.7https://crstodayeurope.com/news/bausch-lomb-highlights-surgical-pharmaceuticals-and-consumer-health-care-innovations-at-aao-2020-virtual-meeting/2478521/daily0.7https://crstodayeurope.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/daily0.7https://crstodayeurope.com/news/lensar-to-presents-several-papers-at-2020-aao-virtual-meeting/2478513/daily0.7https://crstodayeurope.com/news/hoya-surgical-optics-introduces-on-demand-platform-qube-pro-powered-by-eyeflexa/2478514/daily0.7https://crstodayeurope.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/daily0.7https://crstodayeurope.com/news/fda-fast-tracks-novavax-covid-19-vaccine-nvxcov2373/2478517/daily0.7https://crstodayeurope.com/news/fda-authorises-lillys-antibody-therapy-bamlanivimab-for-recently-diagnosed-covid-19/2478512/daily0.7https://crstodayeurope.com/news/health-care-experts-named-to-bidens-covid-19-advisory-board/2478511/daily0.7https://crstodayeurope.com/news/allergan-to-share-new-data-at-american-academy-of-ophthalmology-aao-2020-virtual-meeting/2478510/daily0.7https://crstodayeurope.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/daily0.7https://crstodayeurope.com/news/avellino-introduces-multiplex-respiratory-panel-for-simultaneous-detection-of-covid-19-and-influenza/2478505/daily0.7https://crstodayeurope.com/news/new-alcon-innovations-in-iols-digital-health-solutions-to-be-showcased-at-the-aao-2020-virtual-annual-meeting/2478506/daily0.7https://crstodayeurope.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/daily0.7https://crstodayeurope.com/news/covid-19-vaccine-safety-efforts-to-feature-app-tracking-of-vulnerable-groups/2478501/daily0.7https://crstodayeurope.com/news/first-covid-19-vaccine-doses-to-go-to-health-workers-say-cdc-advisers/2478502/daily0.7https://crstodayeurope.com/news/how-best-to-combat-post-keratoplasty-infections-isnt-always-clear/2478503/daily0.7https://crstodayeurope.com/news/training-the-next-generation-of-ophthalmologists/2478498/daily0.7https://crstodayeurope.com/news/pfizer-goes-solo-on-u-s-shot-distribution-opting-out-of-government-channels/2478499/daily0.7https://crstodayeurope.com/news/llama-nanobodies-may-yield-covid-19-treatment-pitt-scientists-say/2478500/daily0.7https://crstodayeurope.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/daily0.7https://crstodayeurope.com/news/technique-to-regenerate-optic-nerve-offers-hope-for-future-glaucoma-treatment/2478496/daily0.7https://crstodayeurope.com/news/staar-surgical-begins-commercialization-of-evo-viva-presbyopia-correcting-lens/2478495/daily0.7https://crstodayeurope.com/news/what-a-republican-senate-will-mean-for-the-health-care-industry/2478493/daily0.7https://crstodayeurope.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/daily0.7https://crstodayeurope.com/news/vision-impairment-tied-to-less-use-of-cancer-screenings-by-older-adults/2478491/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-receipt-of-a-permanent-category-i-cpt-code-from-the-ama-for-the-insertion-of-intracanalicular-inserts/2478492/daily0.7https://crstodayeurope.com/news/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome/2478487/daily0.7https://crstodayeurope.com/news/curevac-to-move-covid-19-vaccine-into-late-stage-testing-on-positive-early-data/2478489/daily0.7https://crstodayeurope.com/news/regeneron-covid-19-antibody-trial-pauses-enrollment-of-patients-with-high-oxygen-needs/2478484/daily0.7https://crstodayeurope.com/news/internal-documents-reveal-covid-19-hospitalization-data-the-government-keeps-hidden/2478485/daily0.7https://crstodayeurope.com/news/polyactiva-appoints-tracy-valorie-to-its-board-of-directors/2478481/daily0.7https://crstodayeurope.com/news/hospitals-hit-with-ransomware-attacks-as-fbi-warns-of-escalating-threat-to-health-care/2478478/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/daily0.7https://crstodayeurope.com/news/cms-medicare-to-cover-covid-19-vaccine-at-no-cost-to-beneficiaries/2478476/daily0.7https://crstodayeurope.com/news/regenxbio-to-receive-80-million-milestone-payment-from-novartis/2478475/daily0.7https://crstodayeurope.com/news/nicox-granted-new-patent-for-ncx-470-extending-exclusivity-in-europe-to-2039/2478471/daily0.7https://crstodayeurope.com/news/lilly-reaches-deal-to-supply-us-with-covid-19-antibody-treatment-bamlanivimab/2478472/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-initiates-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-ophthalmic-solution-for-the-treatment-of-patients-with-dry-eye-disease/2478473/daily0.7https://crstodayeurope.com/news/norlase-announces-fda-clearance-and-u-s-launch-of-new-lion-laser-system/2478470/daily0.7https://crstodayeurope.com/news/regenerx-joint-venture-enrolls-last-subject-in-phase-3-dry-eye-trial/2478468/daily0.7https://crstodayeurope.com/news/santen-and-aerie-conclude-exclusive-license-agreement-for-rhopressa-and-rocklatan-in-japan-and-several-other-asian-countries/2478469/daily0.7https://crstodayeurope.com/news/allergan-announces-positive-phase-3-topline-results-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478467/daily0.7https://crstodayeurope.com/news/iveena-announces-positive-topline-results-of-ivmed-80-eye-drops-for-keratoconus/2478466/daily0.7https://crstodayeurope.com/news/cvs-pharmacy-launches-quickrenew-at-home-contact-lens-prescription-renewal-tool/2478465/daily0.7https://crstodayeurope.com/news/astrazenecas-covid-19-vaccine-produces-robust-immune-response-in-elderly/2478462/daily0.7https://crstodayeurope.com/news/uk-study-finds-evidence-of-waning-antibody-immunity-to-covid-19-over-time/2478463/daily0.7https://crstodayeurope.com/news/blanchard-contact-lenses-adds-paragon-crt-to-product-portfolio/2478464/daily0.7https://crstodayeurope.com/news/bausch-lomb-introduces-simplifeye-iol-delivery-system-for-envista-toric-and-monofocal-preloaded-iols/2478461/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-fda-approval-of-dry-eye-disease-treatment-eysuvis/2478460/daily0.7https://crstodayeurope.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/daily0.7https://crstodayeurope.com/news/fda-approves-vanda-pharmaceuticals-ind-application-for-vsj-110-for-allergic-conjunctivitis/2478459/daily0.7https://crstodayeurope.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/daily0.7https://crstodayeurope.com/news/nicoxs-ncx-470-receives-approval-by-chinese-authorities-for-local-start-of-mont-blanc-phase-3-trial/2478456/daily0.7https://crstodayeurope.com/news/fda-accepts-santens-nda-for-cyclosporine-topical-ophthalmic-emulsion-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18/2478457/daily0.7https://crstodayeurope.com/news/visus-therapeutics-expands-clinical-advisory-board-with-appointment-of-renowned-ophthalmologists/2478453/daily0.7https://crstodayeurope.com/news/insurers-taking-wait-and-see-approach-to-covid-19-in-2021-aca-exchange-rates-experts/2478454/daily0.7https://crstodayeurope.com/news/moderna-hits-30000-enrollment-target-in-phase-3-coronavirus-vaccine-trial/2478450/daily0.7https://crstodayeurope.com/news/gileads-veklury-becomes-first-treatment-to-receive-fda-approval-for-covid-19/2478451/daily0.7https://crstodayeurope.com/news/nicox-selects-development-candidate-in-a-new-class-of-no-mediated-iop-lowering-agents/2478452/daily0.7https://crstodayeurope.com/news/suspected-control-group-participant-in-astrazeneca-covid-19-vaccine-study-dies-trial-continues/2478449/daily0.7https://crstodayeurope.com/news/rayner-launches-raytrace-premium-iol-calculator-update-to-include-posterior-corneal-astigmatism/2478444/daily0.7https://crstodayeurope.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/daily0.7https://crstodayeurope.com/news/myopia-profile-and-essilor-partner-to-tackle-childhood-myopia-through-education-and-awareness/2478446/daily0.7https://crstodayeurope.com/news/cdc-warns-of-distressing-trend-with-increased-covid-19-cases-across-nearly-75-of-the-country/2478447/daily0.7https://crstodayeurope.com/news/tarsus-pharmaceuticals-announces-closing-of-initial-public-offering/2478442/daily0.7https://crstodayeurope.com/news/the-vision-council-announces-dates-for-the-2021-virtual-executive-summit-january-26-28-2021/2478440/daily0.7https://crstodayeurope.com/news/prevent-blindness-encourages-everyone-to-take-a-screen-time-out/2478441/daily0.7https://crstodayeurope.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/daily0.7https://crstodayeurope.com/news/sources-say-us-study-of-astrazenecas-covid-19-vaccine-may-restart-this-week/2478439/daily0.7https://crstodayeurope.com/news/volunteers-to-be-infected-with-coronavirus-in-worlds-first-human-challenge-trials/2478437/daily0.7https://crstodayeurope.com/news/fundamentalvr-expands-into-ophthalmology/2478436/daily0.7